- Home
- PFLT vs AVXL Comparison
PFLT vs AVXL Comparison
Compare PFLT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- AVXL
- Stock Information
- Founded
- PFLT 2010
- AVXL 2004
- Country
- PFLT United States
- AVXL United States
- Employees
- PFLT N/A
- AVXL N/A
- Industry
- PFLT Finance: Consumer Services
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFLT Finance
- AVXL Health Care
- Exchange
- PFLT Nasdaq
- AVXL Nasdaq
- Market Cap
- PFLT 808.2M
- AVXL 761.3M
- IPO Year
- PFLT N/A
- AVXL N/A
- Fundamental
- Price
- PFLT $10.09
- AVXL $8.56
- Analyst Decision
- PFLT Buy
- AVXL Strong Buy
- Analyst Count
- PFLT 4
- AVXL 2
- Target Price
- PFLT $11.38
- AVXL $44.00
- AVG Volume (30 Days)
- PFLT 928.9K
- AVXL 693.1K
- Earning Date
- PFLT 05-12-2025
- AVXL 05-13-2025
- Dividend Yield
- PFLT 12.20%
- AVXL N/A
- EPS Growth
- PFLT 16.92
- AVXL N/A
- EPS
- PFLT 1.37
- AVXL N/A
- Revenue
- PFLT $215,391,000.00
- AVXL N/A
- Revenue This Year
- PFLT $48.14
- AVXL N/A
- Revenue Next Year
- PFLT $9.03
- AVXL N/A
- P/E Ratio
- PFLT $7.37
- AVXL N/A
- Revenue Growth
- PFLT 47.56
- AVXL N/A
- 52 Week Low
- PFLT $8.82
- AVXL $3.51
- 52 Week High
- PFLT $12.02
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- PFLT 48.50
- AVXL 43.87
- Support Level
- PFLT $9.98
- AVXL $8.20
- Resistance Level
- PFLT $10.18
- AVXL $9.59
- Average True Range (ATR)
- PFLT 0.18
- AVXL 0.42
- MACD
- PFLT 0.07
- AVXL -0.10
- Stochastic Oscillator
- PFLT 81.76
- AVXL 22.50
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.